Trials / Completed
CompletedNCT02161237
Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation
A Multi-center, Randomized, Open-label, Pilot and Exploratory Study Investigating Safety and Efficacy in OPTIMIZEd Dosing of Advagraf® Kidney Transplantation in Asia.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Primary purpose of this study is to compare renal function between subjects receiving optimized dose Advagraf® over 52 weeks after kidney transplantation and subjects receiving standard dose Advagraf®. Pilot results of safety and efficacy in optimized dose Advagraf® over 52 weeks after kidney transplantation will also be obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Advagraf® | oral |
Timeline
- Start date
- 2014-06-26
- Primary completion
- 2016-12-22
- Completion
- 2016-12-22
- First posted
- 2014-06-11
- Last updated
- 2024-10-31
Locations
2 sites across 2 countries: South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02161237. Inclusion in this directory is not an endorsement.